The Claims:

1. A 24 valent pneumococcal conjugate vaccine composition comprising capsular polysaccharide from serotypes of *Streptococcus pneumoniae* conjugated to a carrier protein, wherein the serotypes comprise 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C,19A,19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B.

2. A pneumococcal conjugate vaccine composition as claimed in claim 1, wherein the carrier protein is selected from CRM_{197} or combination of CRM_{197} and PsaA or combination of CRM_{197} and Tetanus toxoid or combination of PsaA and Tetanus toxoid or combination of CRM_{197}, PsaA and Tetanus toxoid.

3. A pneumococcal conjugate vaccine composition as claimed in claim 1 or claim 2, wherein the carrier protein is CRM_{197}, PsaA or combination thereof.

4. A pneumococcal conjugate vaccine composition as claimed in claim 1, wherein capsular polysaccharide from serotypes of *Streptococcus pneumonia* 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C,19A,19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to CRM_{197}.

5. A pneumococcal conjugate vaccine composition as claimed in claim 1, wherein capsular polysaccharide from serotypes of *Streptococcus pneumonia* 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C,19A,19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B are conjugated to PsaA.

6. A pneumococcal conjugate vaccine composition as claimed in claim 1, wherein the vaccine composition is a 24 valent pneumococcal polysaccharide-protein conjugate vaccine composition wherein at least thirteen serotypes are conjugated to CRM_{197} and remaining serotypes are conjugated to PsaA.

7. A pneumococcal conjugate vaccine composition as claimed in claim 6, wherein capsular polysaccharide from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F are conjugated to CRM_{197} and capsular polysaccharide from serotypes 3, 6A, 8, 10A, 11A, 12F, 15A, 23A, 23B, 24F and 35B are conjugated to PsaA.

8. A pneumococcal conjugate vaccine composition as claimed in claim 1 or claim 2, wherein capsular polysaccharide from serotypes 3, 6A, 8, 10A, 11A, 12F, 15A, 23A, 23B, 24F and 35B are conjugated to PsaA and capsular polysaccharide from serotypes 1, 4, 5, 6B, 7F, 9V, 14,

18C, 19A, 19F, 22F, 23F and 33F are conjugated to combination of CRM_{197} and Tetanus toxoid or combination of CRM_{197}, PsaA and Tetanus toxoid.

9. A pneumococcal vaccine composition as claimed in any of the preceding claims, wherein one or more of the pneumococcal polysaccharides are fragmented, each fragmented pneumococcal polysaccharide has an average molecular weight less than that of a native pneumococcal polysaccharide and range from 50 to 1000 kDa.

10. The pneumococcal vaccine composition as claimed in claim 9, wherein the pneumococcal polysaccharides have a molecular weight between 50 and 1000 kDa, preferably, have an average size (Mw) of between 100-1000, 200-800, 250-600, or 300-400, 70-150, or 75-125 kDa.

11. A pneumococcal vaccine composition as claimed in any of the preceding claims, wherein the polysaccharide-protein conjugates have a molecular weight ranging between 500 kDa to 5000 kDa; 1,000 kDa to 10,000 kDa; 1,500 kDa to 15,000 kDa; 2,000 kDa to 20,000 kDa; 2,500 kDa to 25,000 kDa; or 3,000 kDa to 30,000 kDa.

12. A 24 valent pneumococcal conjugate vaccine composition comprising 2.2 µg of each capsular polysaccharide from serotypes of S*treptococcus pneumoniae* 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C,19A,19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B and 4.4 µg of polysaccharide from serotype 6B, wherein each capsular polysaccharide from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F are conjugated to 25 to 40 µg of CRM_{197} carrier protein and each capsular polysaccharide from serotypes 3, 6A, 8, 10A, 11A, 12F, 15A, 23A, 23B, 24F and 35B are conjugated to 25 to 40 µg of PsaA.

13. A 24 valent pneumococcal conjugate vaccine composition comprising 2.2 to 2.4 µg of each capsular polysaccharide from serotypes of S*treptococcus pneumoniae* 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C,19A,19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B and 4.4 µg 6B, wherein each capsular polysaccharide is conjugated to 40 to 80 µg of PsaA.

14. A 24 valent pneumococcal conjugate vaccine composition comprising 2.2 to 2.4 µg of each capsular polysaccharide from serotypes of S*treptococcus pneumoniae* 1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C,19A,19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B and 4.4 µg 6B, wherein each capsular polysaccharide is conjugated to 40 to 80 µg of CRM_{197}.

15. A pneumococcal conjugate vaccine composition as claimed in claims 12 to 14, wherein serotype 15A has a glycerol content in the range of 5-18%.

16. A pneumococcal conjugate vaccine composition as claimed in claims 12 to 14, wherein serotype 35B has a glycerol content in the range of 2-10 %, preferably 2-8%.

17. A pneumococcal conjugate vaccine composition as claimed in any of the preceding claims further comprising one or more of the following: a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient.

18. A pneumococcal conjugate vaccine composition as claimed in 17, wherein the adjuvant is aluminum phosphate.

19. Use of pneumococcal vaccine composition as claimed in any one of the preceding claims in the manufacture of a medicament for preventing or treating a disease caused by *Streptococcus pneumoniae* in a subject.

20. The use of claim 19, wherein the subject is a human, such as an infant (less than about 1 year of age), a toddler (about 12 months to about 24 months of age), a young child (about 2 years to about 5 years of age), an older child (about 5 years to about 13 years of age), an adolescent (about 13 years to about 18 years of age), an adult (about 18 years to about 65 years of age), or an elder (more than about 65 years of age).

21. The use of claim 20, comprising administering the pneumococcal conjugate vaccine composition to the subject as parenterally (e.g. subcutaneously, intramuscularly, intradermally and/or intravenously) or mucosally (e.g., orally and/or nasally).

22. A pneumococcal conjugate vaccine composition as claimed in any of the preceding claims, wherein each dose of the vaccine compositions comprises 0.1 µg to 50 µg of each pneumococcal polysaccharide, 0.1 µg to 10 µg, or 1 µg to 5 µg of each pneumococcal polysaccharide conjugated to each carrier protein comprising 1.5 µg to 70 µg of each carrier protein, more preferably comprising 1.5 µg to 5 µg of each carrier protein.

23. A pneumococcal conjugate vaccine composition as claimed in any of the preceding claims, wherein a percent ratio of protein to polysaccharide (protein/PS) is of 0.3 to 2.0 protein/PS, preferably, 0.5 to 1.5.

24. A method for preparing a 24 valent pneumococcal polysaccharide-protein conjugate composition as claimed in claim 4, wherein the method comprises the steps of:

(a) individually conjugating one or more of twenty-four activated pneumococcal polysaccharides to CRM_{197} carrier protein,

(b) diafiltering and purifying the conjugates using size exclusion chromatography,

(c) analyzing the purified fractions using SEC-MALLS, pooling fractions containing each of the twenty-four conjugates, and filter sterilizing the monovalent conjugate fractions, and

(d) formulating the 24 conjugates obtained in step (a), an adjuvant, one or more excipients, and buffer to prepare the 24 valent pneumococcal polysaccharide-protein conjugate composition.

25. A method for preparing a 24 valent pneumococcal polysaccharide-protein conjugate composition as claimed in claim 1, wherein the method comprises the steps of:

a. individually conjugating one or more of twenty-four activated pneumococcal polysaccharides to an immunogenic carrier protein selected from a group comprising PsaA and CRM_{197},

b. diafiltering and purifying the conjugates using size exclusion chromatography,

c. analyzing the purified fractions using SEC-MALLS, pooling fractions containing each of the twenty-four conjugates, and filter sterilizing the monovalent conjugate fractions, and

d. formulating the twenty-four conjugates obtained in step (a), an adjuvant, one or more excipients, and buffer to prepare the twenty-four valent pneumococcal polysaccharide-protein conjugate composition.

26.A pneumococcal conjugate vaccine composition as claimed in any of the preceding claims, wherein the vaccine is formulated into a unit dose vial, a multiple dose vial, or a pre-filled syringe.

27. A pneumococcal conjugate vaccine composition as claimed in any of the preceding claims, wherein the vaccine further comprise of one or more preservative(s) selected from thiomersal, 2-phenoxyethanol, in an amount ranges from 4 mg/mL to 20 mg/mL.

28. A 24 valent immunogenic composition comprising pneumococcal capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8,9V, 10A, 14, 18C, 19A, 19F, 23F, 11A, 12F, 15A, 22F, 23A, 23B, 24F, 33F and 35B each individually conjugated to CRM_{197}, wherein the composition has pH from 4 to 7 and comprise: 4.4 µg/0.5mL of 6B; 2.2 to 4 µg/0.5mL of all other serotypes; 40 to 80 µg/0.5mL CRM_{197}; 0.2 to 2 mg/0.5mL of aluminum phosphate; 1 to

10 mM succinate buffer; 0.5 to 2.5% w/v sodium chloride; 0.002 to 0.2% w/v polysorbate 80; and 4 mg/mL and 10 mg/0.5mL of 2-phenoxyethanol.

29. A 24 valent immunogenic composition comprising pneumococcal capsular polysaccharides from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F conjugated to CRM_{197} and capsular polysaccharide from serotypes 3, 6A, 8, 10A, 11A, 12F, 15A, 23A, 23B, 24F and 35B conjugated to PsaA, wherein the composition has pH from 4 to 7 and comprise: 4.4 µg/0.5mL of 6B; 2.2 to 4 µg/0.5mL of all other serotypes ; from 20 to 40 µg/0.5 mL CRM_{197}; from 20 to 40 µg/0.5 mL PsaA; 0.2 to 2 mg/0.5mL of aluminum phosphate; 1 to 10 mM succinate buffer; 0.5 to 2.5% w/v sodium chloride; 0.002 to 0.2% w/v polysorbate 80; and 4 mg/mL and 10 mg/0.5mL of 2-phenoxyethanol.

30. A 24 valent immunogenic composition comprising pneumococcal capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8,9V, 10A, 14, 18C, 19A, 19F, 23F, 11A, 12F, 15A, 22F, 23A, 23B, 24F, 33F and 35B each individually conjugated to PsaA, wherein the composition has pH from 4 to 7 and comprise: 4.4 µg/0.5mL of 6B; 2.2 to 4 µg/0.5mL of all other serotypes ; 40 to 80 µg/0.5 mL PsaA; 0.2 to 2 mg/0.5mL of aluminum phosphate; 1 to 10 mM succinate buffer; 0.5 to 2.5% w/v sodium chloride; 0.002 to 0.2% w/v polysorbate 80; and 4 mg/mL and 10 mg/0.5mL of 2-phenoxyethanol.